 Lilliam Ambroggio
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Acquired Infections | 46 | 2026 | 177 | 12.980 |
Why?
| | Pneumonia | 47 | 2026 | 636 | 11.580 |
Why?
| | Anti-Bacterial Agents | 29 | 2026 | 1923 | 4.470 |
Why?
| | Emergency Service, Hospital | 30 | 2026 | 2381 | 2.990 |
Why?
| | Pneumonia, Bacterial | 10 | 2025 | 113 | 2.710 |
Why?
| | Respiratory Tract Infections | 14 | 2026 | 396 | 2.340 |
Why?
| | Child | 105 | 2026 | 22707 | 2.190 |
Why?
| | Infant | 60 | 2026 | 10077 | 1.800 |
Why?
| | Child, Preschool | 61 | 2026 | 11853 | 1.720 |
Why?
| | Severity of Illness Index | 14 | 2025 | 2930 | 1.670 |
Why?
| | Hospitalization | 24 | 2026 | 2460 | 1.480 |
Why?
| | Guideline Adherence | 5 | 2023 | 586 | 1.470 |
Why?
| | Macrolides | 4 | 2021 | 67 | 1.410 |
Why?
| | Pneumonia, Mycoplasma | 5 | 2025 | 55 | 1.390 |
Why?
| | Ultrasonography | 3 | 2024 | 785 | 1.380 |
Why?
| | Wounds, Gunshot | 3 | 2026 | 258 | 1.370 |
Why?
| | Length of Stay | 11 | 2025 | 1349 | 1.330 |
Why?
| | Hospitals, Pediatric | 13 | 2025 | 558 | 1.290 |
Why?
| | Quality Improvement | 8 | 2025 | 1295 | 1.270 |
Why?
| | beta-Lactams | 3 | 2015 | 32 | 1.260 |
Why?
| | Pneumonia, Pneumococcal | 2 | 2025 | 47 | 1.220 |
Why?
| | Streptococcus pneumoniae | 3 | 2025 | 184 | 1.130 |
Why?
| | Asthma | 7 | 2026 | 1797 | 1.130 |
Why?
| | Firearms | 3 | 2026 | 436 | 1.110 |
Why?
| | Propensity Score | 5 | 2025 | 377 | 1.040 |
Why?
| | Biomedical Research | 4 | 2023 | 717 | 1.020 |
Why?
| | Prospective Studies | 35 | 2026 | 8057 | 1.020 |
Why?
| | Humans | 120 | 2026 | 145474 | 1.020 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1581 | 0.990 |
Why?
| | Bacteremia | 4 | 2019 | 222 | 0.970 |
Why?
| | Retrospective Studies | 34 | 2026 | 17291 | 0.950 |
Why?
| | Adolescent | 49 | 2026 | 22529 | 0.950 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 126 | 0.850 |
Why?
| | Male | 66 | 2026 | 72842 | 0.840 |
Why?
| | Patient Readmission | 6 | 2026 | 769 | 0.830 |
Why?
| | Credentialing | 1 | 2024 | 21 | 0.820 |
Why?
| | Catheterization, Peripheral | 1 | 2025 | 120 | 0.820 |
Why?
| | Administration, Oral | 6 | 2026 | 866 | 0.800 |
Why?
| | Outpatients | 4 | 2024 | 447 | 0.790 |
Why?
| | Female | 67 | 2026 | 78844 | 0.780 |
Why?
| | Suicide | 3 | 2025 | 728 | 0.780 |
Why?
| | Mycoplasma pneumoniae | 7 | 2025 | 53 | 0.760 |
Why?
| | Thiamine Deficiency | 1 | 2022 | 9 | 0.730 |
Why?
| | Radiography, Thoracic | 4 | 2022 | 172 | 0.720 |
Why?
| | Point-of-Care Systems | 1 | 2024 | 189 | 0.700 |
Why?
| | Communicable Diseases | 1 | 2023 | 166 | 0.680 |
Why?
| | Evidence-Based Medicine | 2 | 2015 | 740 | 0.670 |
Why?
| | Ambulatory Care | 5 | 2025 | 609 | 0.620 |
Why?
| | Mental Health Services | 1 | 2025 | 473 | 0.620 |
Why?
| | Administration, Intravenous | 3 | 2025 | 172 | 0.610 |
Why?
| | Microbiota | 5 | 2026 | 730 | 0.580 |
Why?
| | Patient Discharge | 3 | 2022 | 992 | 0.560 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 251 | 0.560 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 484 | 0.550 |
Why?
| | Pneumonia, Necrotizing | 1 | 2017 | 1 | 0.530 |
Why?
| | Sepsis | 3 | 2022 | 664 | 0.520 |
Why?
| | Drug Prescriptions | 3 | 2020 | 288 | 0.520 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2023 | 81 | 0.510 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2017 | 26 | 0.510 |
Why?
| | Mass Screening | 3 | 2024 | 1360 | 0.500 |
Why?
| | Pediatrics | 4 | 2024 | 1121 | 0.480 |
Why?
| | Viruses | 3 | 2023 | 165 | 0.470 |
Why?
| | Research Design | 4 | 2021 | 1137 | 0.470 |
Why?
| | Alcoholism | 1 | 2022 | 822 | 0.440 |
Why?
| | Biomarkers | 11 | 2025 | 4295 | 0.440 |
Why?
| | Child, Hospitalized | 4 | 2024 | 54 | 0.410 |
Why?
| | Multiplex Polymerase Chain Reaction | 3 | 2025 | 56 | 0.410 |
Why?
| | Treatment Failure | 3 | 2024 | 360 | 0.400 |
Why?
| | Research | 2 | 2016 | 430 | 0.390 |
Why?
| | ROC Curve | 4 | 2025 | 617 | 0.390 |
Why?
| | Clinical Decision-Making | 4 | 2022 | 363 | 0.390 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2025 | 58 | 0.370 |
Why?
| | Adrenomedullin | 2 | 2021 | 5 | 0.350 |
Why?
| | Virus Diseases | 2 | 2024 | 216 | 0.340 |
Why?
| | Physical Examination | 2 | 2026 | 243 | 0.340 |
Why?
| | Metabolomics | 3 | 2025 | 732 | 0.320 |
Why?
| | Fever | 3 | 2022 | 319 | 0.310 |
Why?
| | Respiratory Sounds | 3 | 2022 | 103 | 0.310 |
Why?
| | Odds Ratio | 3 | 2022 | 1082 | 0.310 |
Why?
| | Hospital Charges | 1 | 2009 | 46 | 0.300 |
Why?
| | Prognosis | 7 | 2023 | 4316 | 0.300 |
Why?
| | Simplexvirus | 1 | 2009 | 82 | 0.300 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2025 | 627 | 0.290 |
Why?
| | United States | 12 | 2024 | 16098 | 0.290 |
Why?
| | Herpes Simplex | 1 | 2009 | 99 | 0.280 |
Why?
| | Critical Illness | 6 | 2025 | 900 | 0.280 |
Why?
| | Health Resources | 1 | 2009 | 130 | 0.280 |
Why?
| | Pandemics | 4 | 2024 | 1707 | 0.270 |
Why?
| | Cohort Studies | 12 | 2025 | 6013 | 0.270 |
Why?
| | Suicidal Ideation | 2 | 2025 | 580 | 0.270 |
Why?
| | Treatment Outcome | 8 | 2024 | 11772 | 0.270 |
Why?
| | Bacteria | 5 | 2026 | 765 | 0.260 |
Why?
| | Feces | 2 | 2021 | 495 | 0.250 |
Why?
| | Utilization Review | 2 | 2018 | 39 | 0.250 |
Why?
| | Case-Control Studies | 6 | 2025 | 3623 | 0.250 |
Why?
| | Drug Therapy, Combination | 3 | 2015 | 1044 | 0.250 |
Why?
| | Practice Patterns, Physicians' | 4 | 2025 | 1371 | 0.240 |
Why?
| | Albuterol | 1 | 2026 | 76 | 0.240 |
Why?
| | Risk Factors | 10 | 2025 | 10885 | 0.240 |
Why?
| | Penicillins | 2 | 2023 | 62 | 0.230 |
Why?
| | Ohio | 2 | 2016 | 146 | 0.230 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 368 | 0.230 |
Why?
| | Carrier State | 1 | 2026 | 78 | 0.230 |
Why?
| | Serogroup | 1 | 2025 | 45 | 0.230 |
Why?
| | Positive-Pressure Respiration | 1 | 2026 | 115 | 0.230 |
Why?
| | Caregivers | 2 | 2026 | 1073 | 0.220 |
Why?
| | Bronchodilator Agents | 1 | 2026 | 187 | 0.220 |
Why?
| | Amoxicillin | 1 | 2025 | 35 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1747 | 0.220 |
Why?
| | Inpatients | 2 | 2021 | 553 | 0.220 |
Why?
| | Influenza, Human | 2 | 2023 | 624 | 0.220 |
Why?
| | Bacteriological Techniques | 1 | 2025 | 66 | 0.210 |
Why?
| | Nasal Mucosa | 1 | 2025 | 112 | 0.210 |
Why?
| | Interrupted Time Series Analysis | 1 | 2024 | 75 | 0.210 |
Why?
| | Protein Precursors | 2 | 2021 | 136 | 0.210 |
Why?
| | Asymptomatic Infections | 1 | 2024 | 37 | 0.210 |
Why?
| | Infant, Newborn | 7 | 2025 | 6447 | 0.210 |
Why?
| | Critical Pathways | 1 | 2025 | 109 | 0.200 |
Why?
| | Trachea | 1 | 2026 | 258 | 0.200 |
Why?
| | Intensive Care Units, Pediatric | 3 | 2025 | 288 | 0.200 |
Why?
| | Diagnostic Errors | 1 | 2025 | 178 | 0.200 |
Why?
| | Logistic Models | 4 | 2021 | 2134 | 0.190 |
Why?
| | Nervous System Diseases | 2 | 2016 | 286 | 0.190 |
Why?
| | Family Characteristics | 1 | 2024 | 195 | 0.190 |
Why?
| | Health Education | 1 | 2026 | 346 | 0.190 |
Why?
| | Pennsylvania | 2 | 2015 | 138 | 0.190 |
Why?
| | Pneumonia, Aspiration | 2 | 2019 | 16 | 0.180 |
Why?
| | Thiamine | 1 | 2022 | 19 | 0.180 |
Why?
| | Coinfection | 1 | 2024 | 143 | 0.180 |
Why?
| | Delphi Technique | 1 | 2024 | 332 | 0.180 |
Why?
| | Consensus | 1 | 2024 | 477 | 0.180 |
Why?
| | Follow-Up Studies | 4 | 2022 | 5423 | 0.170 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 139 | 0.170 |
Why?
| | Pleural Effusion | 1 | 2022 | 59 | 0.170 |
Why?
| | Suicide, Attempted | 1 | 2025 | 423 | 0.170 |
Why?
| | Heart Defects, Congenital | 1 | 2009 | 910 | 0.170 |
Why?
| | Nucleic Acids | 1 | 2022 | 70 | 0.170 |
Why?
| | Arthritis, Infectious | 1 | 2022 | 76 | 0.170 |
Why?
| | Safety | 1 | 2023 | 358 | 0.170 |
Why?
| | Blood Culture | 2 | 2019 | 27 | 0.160 |
Why?
| | Pediatric Emergency Medicine | 1 | 2021 | 24 | 0.160 |
Why?
| | Aftercare | 1 | 2022 | 222 | 0.160 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 227 | 0.160 |
Why?
| | Quality of Life | 2 | 2023 | 3204 | 0.160 |
Why?
| | Gastroenteritis | 1 | 2021 | 63 | 0.160 |
Why?
| | Pseudomonas Infections | 1 | 2022 | 230 | 0.160 |
Why?
| | International Cooperation | 1 | 2021 | 197 | 0.160 |
Why?
| | Cytomegalovirus Vaccines | 1 | 2019 | 5 | 0.150 |
Why?
| | Proteome | 1 | 2024 | 514 | 0.150 |
Why?
| | Osteomyelitis | 1 | 2022 | 145 | 0.150 |
Why?
| | State Medicine | 1 | 2019 | 26 | 0.150 |
Why?
| | Societies | 1 | 2019 | 40 | 0.150 |
Why?
| | Clinical Deterioration | 1 | 2019 | 10 | 0.150 |
Why?
| | Intensive Care Units | 3 | 2021 | 924 | 0.150 |
Why?
| | Public Health | 1 | 2024 | 572 | 0.150 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 74 | 0.150 |
Why?
| | Physicians | 2 | 2021 | 955 | 0.140 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2018 | 20 | 0.140 |
Why?
| | Central Nervous System Diseases | 1 | 2019 | 74 | 0.140 |
Why?
| | Diarrhea | 1 | 2020 | 193 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2026 | 735 | 0.140 |
Why?
| | Prednisolone | 2 | 2020 | 67 | 0.140 |
Why?
| | Cytomegalovirus | 1 | 2019 | 168 | 0.140 |
Why?
| | Infectious Disease Medicine | 1 | 2018 | 12 | 0.140 |
Why?
| | Influenza B virus | 1 | 2018 | 47 | 0.140 |
Why?
| | Cross-Sectional Studies | 6 | 2026 | 5904 | 0.140 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2018 | 50 | 0.140 |
Why?
| | Anti-Asthmatic Agents | 1 | 2020 | 260 | 0.130 |
Why?
| | Reproducibility of Results | 4 | 2026 | 3413 | 0.130 |
Why?
| | Observer Variation | 2 | 2016 | 357 | 0.130 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 291 | 0.130 |
Why?
| | Prednisone | 2 | 2020 | 224 | 0.130 |
Why?
| | Proteomics | 1 | 2024 | 1188 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 206 | 0.130 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 221 | 0.130 |
Why?
| | Pilot Projects | 1 | 2023 | 1891 | 0.130 |
Why?
| | Cytokines | 1 | 2025 | 2067 | 0.130 |
Why?
| | Immunization Schedule | 1 | 2018 | 186 | 0.120 |
Why?
| | Antibody Formation | 1 | 2018 | 288 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6066 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2018 | 159 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2017 | 305 | 0.120 |
Why?
| | Dexamethasone | 2 | 2020 | 365 | 0.120 |
Why?
| | Models, Statistical | 1 | 2020 | 671 | 0.120 |
Why?
| | Intersectoral Collaboration | 1 | 2016 | 64 | 0.120 |
Why?
| | Patient Transfer | 1 | 2019 | 211 | 0.120 |
Why?
| | Mental Disorders | 1 | 2025 | 1163 | 0.120 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 480 | 0.120 |
Why?
| | Health Services Research | 1 | 2018 | 391 | 0.120 |
Why?
| | Anaphylaxis | 1 | 2017 | 102 | 0.120 |
Why?
| | Efficiency, Organizational | 1 | 2016 | 141 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 328 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 2 | 2017 | 364 | 0.110 |
Why?
| | Hospitalists | 1 | 2019 | 267 | 0.110 |
Why?
| | Emergency Medicine | 1 | 2018 | 282 | 0.110 |
Why?
| | Azithromycin | 2 | 2025 | 101 | 0.110 |
Why?
| | Inservice Training | 1 | 2015 | 118 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1547 | 0.100 |
Why?
| | Hypoxia | 2 | 2024 | 1199 | 0.100 |
Why?
| | Societies, Medical | 1 | 2018 | 899 | 0.100 |
Why?
| | Influenza Vaccines | 1 | 2018 | 534 | 0.100 |
Why?
| | Palliative Care | 1 | 2021 | 1020 | 0.090 |
Why?
| | Precision Medicine | 1 | 2017 | 459 | 0.090 |
Why?
| | Ethics, Research | 1 | 2012 | 31 | 0.090 |
Why?
| | Binomial Distribution | 1 | 2012 | 8 | 0.090 |
Why?
| | Nasopharynx | 2 | 2023 | 72 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1997 | 0.090 |
Why?
| | Age Factors | 2 | 2022 | 3342 | 0.090 |
Why?
| | Linear Models | 1 | 2015 | 845 | 0.090 |
Why?
| | Penicillin Resistance | 1 | 2012 | 9 | 0.090 |
Why?
| | Cystic Fibrosis | 1 | 2022 | 1161 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 195 | 0.090 |
Why?
| | Academic Medical Centers | 1 | 2015 | 554 | 0.090 |
Why?
| | Medical Informatics | 1 | 2012 | 99 | 0.090 |
Why?
| | Drug Therapy | 1 | 2012 | 84 | 0.090 |
Why?
| | Vulnerable Populations | 1 | 2012 | 176 | 0.080 |
Why?
| | Comparative Effectiveness Research | 1 | 2012 | 168 | 0.080 |
Why?
| | Metagenomics | 2 | 2023 | 149 | 0.080 |
Why?
| | Plasma | 1 | 2012 | 223 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 2 | 2024 | 2769 | 0.080 |
Why?
| | C-Reactive Protein | 2 | 2025 | 422 | 0.080 |
Why?
| | Information Systems | 1 | 2009 | 56 | 0.080 |
Why?
| | Acyclovir | 1 | 2009 | 98 | 0.070 |
Why?
| | Health Care Costs | 1 | 2012 | 425 | 0.070 |
Why?
| | Patient Safety | 1 | 2012 | 356 | 0.070 |
Why?
| | Risk Assessment | 3 | 2025 | 3747 | 0.070 |
Why?
| | Overweight | 1 | 2012 | 614 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1061 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2025 | 1508 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 848 | 0.060 |
Why?
| | Respiration, Artificial | 2 | 2023 | 713 | 0.060 |
Why?
| | Databases, Factual | 1 | 2012 | 1490 | 0.060 |
Why?
| | Time Factors | 3 | 2024 | 7123 | 0.060 |
Why?
| | Lung | 3 | 2024 | 4106 | 0.060 |
Why?
| | Chemokine CXCL10 | 1 | 2025 | 39 | 0.050 |
Why?
| | Video Recording | 1 | 2026 | 217 | 0.050 |
Why?
| | Hospital Mortality | 2 | 2020 | 1038 | 0.050 |
Why?
| | Respiratory Rate | 1 | 2024 | 23 | 0.050 |
Why?
| | Clinical Competence | 1 | 2012 | 1243 | 0.050 |
Why?
| | Arkansas | 1 | 2024 | 23 | 0.050 |
Why?
| | Adult | 6 | 2026 | 40777 | 0.050 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 64 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2009 | 769 | 0.050 |
Why?
| | Uncertainty | 1 | 2024 | 146 | 0.050 |
Why?
| | Young Adult | 4 | 2025 | 14218 | 0.050 |
Why?
| | Canada | 1 | 2024 | 431 | 0.050 |
Why?
| | Cotinine | 1 | 2023 | 77 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 48 | 0.050 |
Why?
| | Tachypnea | 1 | 2022 | 3 | 0.050 |
Why?
| | Viral Load | 1 | 2024 | 526 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 67 | 0.040 |
Why?
| | Smoke | 1 | 2023 | 148 | 0.040 |
Why?
| | Gestalt Theory | 1 | 2021 | 2 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2023 | 977 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2026 | 2062 | 0.040 |
Why?
| | Disease Outbreaks | 1 | 2024 | 419 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2024 | 558 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2026 | 1111 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2022 | 167 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 442 | 0.040 |
Why?
| | Feedback | 1 | 2021 | 180 | 0.040 |
Why?
| | Emergency Treatment | 1 | 2021 | 123 | 0.040 |
Why?
| | Calcitonin | 1 | 2020 | 27 | 0.040 |
Why?
| | Medicaid | 1 | 2024 | 467 | 0.040 |
Why?
| | Documentation | 1 | 2022 | 199 | 0.040 |
Why?
| | Pneumocystis Infections | 1 | 2019 | 1 | 0.040 |
Why?
| | Heart Rate | 1 | 2024 | 855 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 147 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 364 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 107 | 0.040 |
Why?
| | Transcriptome | 1 | 2026 | 1038 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2020 | 265 | 0.040 |
Why?
| | Regression Analysis | 1 | 2022 | 1001 | 0.040 |
Why?
| | Central Venous Catheters | 1 | 2020 | 53 | 0.040 |
Why?
| | Pseudomonas aeruginosa | 1 | 2022 | 395 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 1036 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2026 | 1767 | 0.040 |
Why?
| | Obesity | 1 | 2012 | 3116 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 782 | 0.040 |
Why?
| | Pneumonia, Viral | 1 | 2024 | 389 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2019 | 316 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 507 | 0.040 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2018 | 38 | 0.030 |
Why?
| | Data Display | 1 | 2018 | 20 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2018 | 219 | 0.030 |
Why?
| | Gene Expression | 1 | 2022 | 1476 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1041 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2026 | 1419 | 0.030 |
Why?
| | Bias | 1 | 2017 | 197 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 326 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2017 | 420 | 0.030 |
Why?
| | Colorado | 1 | 2026 | 4553 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 867 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2018 | 336 | 0.030 |
Why?
| | Data Collection | 1 | 2018 | 640 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2019 | 870 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2018 | 674 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2018 | 892 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2923 | 0.020 |
Why?
| | Prevalence | 1 | 2020 | 2865 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1996 | 0.020 |
Why?
| | Aged | 2 | 2022 | 26153 | 0.020 |
Why?
| | Primary Health Care | 1 | 2020 | 1735 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 7202 | 0.010 |
Why?
| | Registries | 1 | 2012 | 2406 | 0.010 |
Why?
|
|
Ambroggio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|